These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 12089993

  • 1. [Prognosis and treatment of membranous glomerulonephritis-a 5-year prospective study].
    Covic A, Căruntu ID, Marian D, Volovăţ C, Ghiciuc C, Costin C, Florea L, Cotuţiu C, Covic M.
    Rev Med Chir Soc Med Nat Iasi; 2000; 104(2):63-74. PubMed ID: 12089993
    [Abstract] [Full Text] [Related]

  • 2. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
    Branten AJ, Wetzels JF.
    Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
    [Abstract] [Full Text] [Related]

  • 3. Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study.
    Goumenos DS, Ahuja M, Davlouros P, El Nahas AM, Brown CB.
    Clin Nephrol; 2006 May; 65(5):317-23. PubMed ID: 16724651
    [Abstract] [Full Text] [Related]

  • 4. Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone.
    Eriguchi M, Oka H, Mizobuchi T, Kamimura T, Sugawara K, Harada A.
    Nephrol Dial Transplant; 2009 Oct; 24(10):3082-8. PubMed ID: 19465558
    [Abstract] [Full Text] [Related]

  • 5. Immunosuppressive therapy with cyclophosphamide and prednisolone in severe idiopathic membranous nephropathy.
    Kibriya MG, Tishkov I, Nikolov D.
    Nephrol Dial Transplant; 1994 Oct; 9(2):138-43. PubMed ID: 8190328
    [Abstract] [Full Text] [Related]

  • 6. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis.
    Dumoulin A, Hill GS, Montseny JJ, Meyrier A.
    Am J Kidney Dis; 2003 Jan; 41(1):38-48. PubMed ID: 12500220
    [Abstract] [Full Text] [Related]

  • 7. Application of artificial neural networks in estimating predictive factors and therapeutic efficacy in idiopathic membranous nephropathy.
    Naumovic R, Furuncic D, Jovanovic D, Stosovic M, Basta-Jovanovic G, Lezaic V.
    Biomed Pharmacother; 2010 Nov; 64(9):633-8. PubMed ID: 20888177
    [Abstract] [Full Text] [Related]

  • 8. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate.
    du Buf-Vereijken PW, Branten AJ, Wetzels JF, Membranous Nephropathy Study Group.
    Nephrol Dial Transplant; 2004 May; 19(5):1142-8. PubMed ID: 14993502
    [Abstract] [Full Text] [Related]

  • 9. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial.
    Hofstra JM, Branten AJ, Wirtz JJ, Noordzij TC, du Buf-Vereijken PW, Wetzels JF.
    Nephrol Dial Transplant; 2010 Jan; 25(1):129-36. PubMed ID: 19666912
    [Abstract] [Full Text] [Related]

  • 10. The therapy of idiopathic membranous glomerulonephritis.
    Glassock RJ.
    Semin Nephrol; 1991 Mar; 11(2):138-47. PubMed ID: 2034923
    [Abstract] [Full Text] [Related]

  • 11. Immunosuppressive treatment of the glomerulonephritis of systemic lupus.
    Faedda R, Palomba D, Satta A, Pirisi M, Tanda F, Bartoli E.
    Clin Nephrol; 1995 Dec; 44(6):367-75. PubMed ID: 8719548
    [Abstract] [Full Text] [Related]

  • 12. The effect of treatment with prednisolone or cyclophosphamide-warfarin-dipyridamole combination on the outcome of patients with membranous nephropathy.
    Shearman JD, Yin ZG, Aarons I, Smith PS, Woodroffe AJ, Clarkson AR.
    Clin Nephrol; 1988 Dec; 30(6):320-9. PubMed ID: 3243041
    [Abstract] [Full Text] [Related]

  • 13. [Clinical outcome assessment of membranous nephropathy].
    Kumagai T, Shimizu H, Nishi T, Mise N, Tagawa H, Sugimoto T.
    Nihon Jinzo Gakkai Shi; 2005 Dec; 47(8):870-5. PubMed ID: 16408431
    [Abstract] [Full Text] [Related]

  • 14. Effective treatment administration of cyclophosphamide in membranous nephropathy.
    Dede F, Ayili D, Sahiner S.
    J Nephrol; 2008 Dec; 21(4):560-5. PubMed ID: 18651546
    [Abstract] [Full Text] [Related]

  • 15. Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria.
    Li X, Lv R, He Q, Li H, Du X, Lin W, Li Q, He X, Wang S, Chen J.
    J Nephrol; 2008 Dec; 21(4):584-91. PubMed ID: 18651550
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity.
    du Buf-Vereijken PW, Wetzels JF.
    Nephrol Dial Transplant; 2004 Aug; 19(8):2036-43. PubMed ID: 15187191
    [Abstract] [Full Text] [Related]

  • 17. Cyclosporin A treatment for idiopathic membranous nephropathy.
    Yao X, Chen H, Wang Q, Tang Z, Hu W, Yin G, Liu Z, Li L.
    Chin Med J (Engl); 2001 Dec; 114(12):1305-8. PubMed ID: 11793859
    [Abstract] [Full Text] [Related]

  • 18. Immunosuppressive treatment of the nephrotic syndrome due to mesangial lesions.
    Faedda R, Pirisi M, Satta A, Tanda F, Bartoli E.
    Clin Nephrol; 1996 Oct; 46(4):237-44. PubMed ID: 8905208
    [Abstract] [Full Text] [Related]

  • 19. [The late results of treating membranous glomerulonephritis].
    Belovezhdov N, Robeva R, Dimitrova V.
    Vutr Boles; 1990 Oct; 29(3):53-60. PubMed ID: 2284800
    [Abstract] [Full Text] [Related]

  • 20. Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: A 3-year prospective study.
    Naumovic R, Jovanovic D, Pavlovic S, Stosovic M, Marinkovic J, Basta-Jovanovic G.
    Biomed Pharmacother; 2011 Mar; 65(2):105-10. PubMed ID: 21109389
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.